» Articles » PMID: 29213258

The Complexity of Antibody Responses Elicited Against the Respiratory Syncytial Virus Glycoproteins in Hospitalized Children Younger Than 2 Years

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2017 Dec 8
PMID 29213258
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The influence of age and maternal antibodies on the antibody responses to human respiratory syncytial virus (hRSV) glycoproteins in very young children has been a matter of controversy. Both, immaturity of the immune system at very early age and suppression of the host immune response by high level of maternal antibodies have been claimed to limit the host antibody response to virus infection and to jeopardize the use of hRSV vaccines under development in that age group. Hence, the antibody responses to the two major hRSV glycoproteins (F and G) were evaluated in children younger than 2 years, hospitalized with laboratory confirmed hRSV bronchiolitis. A strong negative correlation was found between the titre of circulating ELISA antibodies directed against either prefusion or postfusion F in the acute phase, but not age, and their fold change at convalescence. These changes correlated also with the level of circulating neutralizing antibodies in sera. As reported in adults, most neutralizing antibodies in a subset of tested sera could not be depleted with postfusion F, suggesting that they were mostly directed against prefusion-specific epitopes. In contrast, a weak negative association was found for group-specific anti-G antibodies in the acute phase and their fold change at convalescence only after correcting for the antigenic group of the infecting virus. In addition, large discrepancies were observed in some individuals between the antibody responses specific for F and G glycoproteins. These results illustrate the complexity of the anti-hRSV antibody responses in children experiencing a primary severe infection and the influence of preexisting maternal antibodies on the host response, factors that should influence hRSV serological studies as well as vaccine development.

Citing Articles

Development and comparison of immunologic assays to detect primary RSV infections in infants.

Anderson L, Jadhao S, Hussaini L, Ha B, McCracken C, Gibson T Front Immunol. 2024; 14:1332772.

PMID: 38283339 PMC: 10811012. DOI: 10.3389/fimmu.2023.1332772.


All Eyes on the Prefusion-Stabilized F Construct, but Are We Missing the Potential of Alternative Targets for Respiratory Syncytial Virus Vaccine Design?.

Schaerlaekens S, Jacobs L, Stobbelaar K, Cos P, Delputte P Vaccines (Basel). 2024; 12(1).

PMID: 38250910 PMC: 10819635. DOI: 10.3390/vaccines12010097.


Long-Lasting Protection Induced by a Polyanhydride Nanovaccine against Respiratory Syncytial Virus in an Outbred Mouse Model.

Stephens L, Ross K, McLellan J, Narasimhan B, Varga S J Virol. 2022; 96(22):e0150222.

PMID: 36314826 PMC: 9683007. DOI: 10.1128/jvi.01502-22.


Transplacental Antibody Transfer of Respiratory Syncytial Virus Specific IgG in Non-Human Primate Mother-Infant Pairs.

Citron M, McAnulty J, Callahan C, Knapp W, Fontenot J, Morales P Pathogens. 2021; 10(11).

PMID: 34832599 PMC: 8624788. DOI: 10.3390/pathogens10111441.


During the COVID-19 pandemic where has respiratory syncytial virus gone?.

Di Mattia G, Nenna R, Mancino E, Rizzo V, Pierangeli A, Villani A Pediatr Pulmonol. 2021; 56(10):3106-3109.

PMID: 34273135 PMC: 8441855. DOI: 10.1002/ppul.25582.


References
1.
Meier S, Guthe S, Kiefhaber T, Grzesiek S . Foldon, the natural trimerization domain of T4 fibritin, dissociates into a monomeric A-state form containing a stable beta-hairpin: atomic details of trimer dissociation and local beta-hairpin stability from residual dipolar couplings. J Mol Biol. 2004; 344(4):1051-69. DOI: 10.1016/j.jmb.2004.09.079. View

2.
Magro M, Mas V, Chappell K, Vazquez M, Cano O, Luque D . Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A. 2012; 109(8):3089-94. PMC: 3286924. DOI: 10.1073/pnas.1115941109. View

3.
Nyiro J, Sande C, Mutunga M, Kiyuka P, Munywoki P, Scott J . Absence of Association between Cord Specific Antibody Levels and Severe Respiratory Syncytial Virus (RSV) Disease in Early Infants: A Case Control Study from Coastal Kenya. PLoS One. 2016; 11(11):e0166706. PMC: 5113039. DOI: 10.1371/journal.pone.0166706. View

4.
Murata Y, Lightfoote P, Falsey A, Walsh E . Identification of and human serum reactogenicity to neutralizing epitopes within the central unglycosylated region of the respiratory syncytial virus attachment protein. Clin Vaccine Immunol. 2010; 17(4):695-7. PMC: 2849351. DOI: 10.1128/CVI.00432-09. View

5.
Hendry R, Burns J, Walsh E, Graham B, Wright P, Hemming V . Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. J Infect Dis. 1988; 157(4):640-7. DOI: 10.1093/infdis/157.4.640. View